T1	Participants 363 378	Eligible adults
T2	Participants 767 775	patients
T3	Participants 1027 1040	placebo group
T4	Participants 1046 1061	50 mg/day group
T5	Participants 1311 1319	patients
T6	Participants 1390 1406	those on placebo
